StockData
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc. (XENE) stock

XENENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$40.48−0.52 (-1.26%)

Close on Nov 13, 2026Market cap $3.92BP/E –Yield –

Xenon Pharmaceuticals operating margin

Operating margin is operating income as a percentage of revenue.

Xenon Pharmaceuticals's operating margin for the twelve months ending Dec 31, 2025 was -4974.3%. For fiscal 2025 it was -4974.3%, against -1368.9% the year before. The highest annual figure on record is 39.1% in fiscal 2014.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-4974.3%−3605.4
FY2022Dec 31, 2022-1368.9%−940.5
FY2021Dec 31, 2021-428.4%−331.1
FY2020Dec 31, 2020-97.3%+529.7
FY2019Dec 31, 2019-627.0%+9847.3
FY2017Dec 31, 2017-10474.3%−9097.8
FY2016Dec 31, 2016-1376.4%−1316.3
FY2015Dec 31, 2015-60.1%−99.2
FY2014Dec 31, 201439.1%+3.6
FY2013Dec 31, 201335.5%+57.5
FY2012Dec 31, 2012-22.0%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2025Mar 31, 2025-969.8%−305.2
Q3 FY2022Sep 30, 2022-28884.8%−28692.8
Q2 FY2022Jun 30, 2022-5655.8%−4641.4
Q1 FY2022Mar 31, 2022-198.1%+170.4
Q4 FY2021Dec 31, 2021-664.7%−413.7
Q3 FY2021Sep 30, 2021-192.0%−44.0
Q2 FY2021Jun 30, 2021-1014.3%−1009.5
Q1 FY2021Mar 31, 2021-368.5%−255.0
Q4 FY2020Dec 31, 2020-250.9%+97.5
Q3 FY2020Sep 30, 2020-148.0%+107.8
Q2 FY2020Jun 30, 2020-4.8%+50313.9
Q1 FY2020Mar 31, 2020-113.5%+3160.7
Q4 FY2019Dec 31, 2019-348.4%+52271.6
Q3 FY2019Sep 30, 2019-255.7%+49663.0
Q4 FY2017Dec 31, 2017-50318.8%−48866.1
Q3 FY2017Sep 30, 2017-3274.2%–
Q2 FY2017Jun 30, 2017-52620.0%–
Q1 FY2017Mar 31, 2017-49918.8%–
Q4 FY2016Dec 31, 2016-1452.7%–

More Xenon Pharmaceuticals figures

See a number that looks wrong?